2-(4-Fluorophenyl)-5-[(5-yodo-2-methylphenyl)methyl]thiophene CAS 898566-17-1 Pite> 98.0% (HPLC)

Deskripsyon kout:

Non chimik: 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene

CAS: 898566-17-1

Pite:> 98.0% (HPLC)

Aparans: blan pou jòn pal Crystalline poud

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Entèmedyè ki gen rapò ak ekipman pou manifakti:
4-Fluorophenylboronic Asid CAS: 1765-93-1
2-(4-Fluorophenyl)tiofèn CAS: 58861-48-6
2,3,4,6-Tetrakis-O-trimethylsilil-D-gluconolactone CAS: 32384-65-9
5-Iodo-2-Methylbenzoic Asid CAS 54811-38-0
2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene CAS: 1030825-20-7
2-(4-Fluorophenyl)-5-[(5-yodo-2-methylphenyl)methyl]thiophene CAS: 898566-17-1
CAS: 842133-18-0
CAS: 928672-86-0

Pwopriyete chimik:

Non Chimik	2-(4-Fluorophenyl)-5-[(5-yodo-2-methylphenyl)methyl]tiofèn
Nimewo CAS	898566-17-1
Nimewo CAT	RF-PI1501
Estati Stock	Nan Stock, Pwodiksyon Echèl Jiska Tòn
Fòmil molekilè	C18H14FIS
Pwa molekilè	408.27
Pwen k ap fonn	109.0 ~ 110.0 ℃
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Poud cristalline blan a jòn pal
Pite / Metòd analiz	>98.0% (HPLC)
Pèt sou siye	<1.00%
Enpurte total	<2.00%
Tès Creole	Enterprise Standard

Pake & Depo:

Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite

Avantaj:

FAQ:

Aplikasyon:

2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene (CAS: 898566-17-1) se yon ajan antidyabetik ak yon entèmedyè nan API (CAS: 842133-18-0) .(CAS: 842133-18-0) se yon inibitè sodyòm/glikoz cotransporter 2 (SGLT2) ak yon kandida pou tretman dyabèt tip 2 ak obezite.(CAS: 842133-18-0) se yon dwòg dyabèt oral yon fwa chak jou, ki travay pa anpeche sodyòm glikoz co-transporter 2 (SGLT2) kòm yon nouvo dwòg.(CAS: 842133-18-0) kapab bese nivo glikoz nan san an pa entèdi reabsorption glikoz nan san nan ren yo epi ogmante eskresyon glikoz nan san nan pipi.Li se premye inibitè FDA apwouve pou SGLT2 epi li itilize pou trete pasyan adilt ki gen dyabèt tip 2.